Regulatory & Legal Archive
13-09-2017 EMA: On the 22 August 2017, the European Commission granted a Marketing Authorization for Kisqali (ribociclib), in combination with an aromatase inhibitor is indicated for the treatment of postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer as initial endocrine based therapy. The Marketing Authorization Holder for this medicinal product is Novartis Europharm Ltd.
08-09-2017 MoH: Draft Order to amend MoH Order 183/2005 regarding the approval of the organization and functioning regulation, the organigram, the composition of the Scientific Council of the National Transplant Agency, as well as the attributions of the Deputy Director Strategy - Management of the National Transplant Agency
In an unexpected move, just before the end of 2011, ...
Improving expenditure efficiency has been, for a ver...
Your Portal Link to Mass Media Universe.
Valuable Quarterly Romanian Market Analysis.
Ask the analyst
Tailor-made advice for you